Vertex Pharmaceuticals Inc / Ma (VRTX): Joshua S Boger , director of Vertex Pharmaceuticals Inc / Ma sold 5,130 shares on Jun 22, 2016. The Insider selling transaction was reported by the company on Jun 24, 2016 to the Securities and Exchange Commission. The shares were sold at $87.19 per share for a total value of $444,312.19 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 17, 2016, Joshua S Boger (director) sold 5,130 shares at $91.18 per share price.On May 18, 2016, Amit Sachdev (EVP, Policy, Access & Value) sold 117 shares at $81.67 per share price.Also, On May 18, 2016, Paul M Silva (SVP & Corp Controller) sold 202 shares at $82.06 per share price.On May 18, 2016, Ian F Smith (EVP & CFO) sold 202 shares at $82.06 per share price.
Shares of Vertex Pharmaceuticals Incorporated (VRTX) ended Friday, Jun 24, 2016 session in red amid volatile trading. The shares closed down -6.3 points or -7.14% at $81.9 with 22,98,494 shares getting traded. Post opening the session at $83.58, the shares hit an intraday low of $81.82 and an intraday high of $85.79 and the price vacillated in this range throughout the day. The company has a market cap of $20,258 M and the number of outstanding shares has been calculated to be 24,73,49,860 shares. The 52-week high of Vertex Pharmaceuticals Incorporated is $143.45 and the 52-week low is $75.9.
Company has been under the radar of several Street Analysts.Vertex Pharmaceuticals Incorporated is Reiterated by RBC Capital Mkts to Outperform while Lowering the Price Target of the company shares to $ 115 from a previous price target of $135 . The Rating was issued on Apr 28, 2016.Vertex Pharmaceuticals Incorporated is Reiterated by Barclays to Overweight while Lowering the Price Target of the company shares to $ 110 from a previous price target of $135 . The Rating was issued on Apr 28, 2016.Vertex Pharmaceuticals Incorporated is Downgraded by Goldman to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Apr 28, 2016.Vertex Pharmaceuticals Incorporated is Reiterated by Stifel to Buy while Lowering the Price Target of the company shares to $ 108 from a previous price target of $140 . The Rating was issued on Apr 1, 2016.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Companys product KALYDECO is available in the market.